This activity was originally presented live at Asembia's AXS26 Summit in Las Vegas, Nevada
Program Description
Psoriasis is a chronic, immune-mediated inflammatory disease characterized by painful or pruritic plaques and a substantial psychosocial burden that can significantly impact quality of life. While topical therapies are often used initially, many patients require escalation to systemic treatment due to inadequate disease control, adverse effects, or practical limitations. Although biologic therapies have improved outcomes for many patients, treatment selection remains complex, and there is no single, universally accepted algorithm to guide optimal therapy sequencing. As the treatment landscape continues to evolve, the availability of targeted oral therapies such as tyrosine kinase 2 (TYK2) inhibitors has expanded therapeutic options and increased opportunities for individualized, patient-centered care. This activity will examine the role of TYK2 inhibition within the broader psoriasis treatment paradigm and how these agents may be integrated into clinical practice. Through interactive, case-based discussions, expert faculty will explore treatment sequencing, therapy initiation and switching, and real-world challenges including prior authorization navigation, counseling on oral versus injectable preferences, and managing patient expectations for treatment outcomes.
Target audience: Specialty pharmacists
Type of Activity: Application
Release date: May 11, 2026
Expiration date: May 11, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the clinical and pathophysiologic characteristics of psoriasis and when and why to escalate therapy beyond topicals
- Demonstrate familiarity with the mechanisms of action and clinical data of emerging TYK2 inhibitors, and differentiate them from other systemic therapies
- Provide insight and guidance when navigating the evolving treatment landscape, including patient counseling, payer requirements, and adherence strategies
Aderonke Adeboye, PharmD, BCPS
Clinical Pharmacy Specialist, Dermatology
Emory University Hospital Midtown
Atlanta, GA
Jamie L. McConaha, PharmD, CDCES, FCCP, BCACP
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Pittsburgh, PA
Accreditation
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-114-H01-P. The activity is available for CE credit through May 11, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
The following contributors have no relevant financial relationships with ineligible companies to disclose:
Faculty
Aderonke Adeboye, PharmD, BCPS
Jamie L. McConaha, PharmD, CDCES, FCCP, BCACP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here